Featured publications

• Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation

  Authors: Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M.

  Reference: AMERICAN JOURNAL OF TRANSPLANTATION 2019; 19(11):3176-3184.

• Insights into the success and failure of systemic therapy for hepatocellular carcinoma

  Authors: Bruix J, da Fonseca LG, Reig M.

  Reference: Nature Reviews Gastroenterology & Hepatology 2019; 16(10):617-630.

• Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma

  Authors: Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J.

  Reference: GASTROENTEROLOGY 2019; 156(6):1731-1741.

• Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib

  Authors: Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M.

  Reference: ALIMENTARY PHARMACOLOGY & THERAPEUTICS 2019; 49(5):482-491.

• Hepatocellular carcinoma

  Authors: Forner A; Reig M; Bruix J.

  Reference: LANCET 2018; 391(10127):1301-1314.

• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

  Authors: Bruix, Jordi; Qin, Shukui; Merle, Philippe; Granito, Alessandro; Huang, Yi-Hsiang; Bodoky, Gyrogy; Pracht, Marc; Yokosuka, Osamu; Rosmorduc, Olivier; Breder, Valeriy; Gerolami, Rene; Masi, Gianluca; Ross, Paul J; Song, Tianqiang; Bronowicki, Jean-Pierre; Ollivier-Hourmand, Isabelle; Kudo, Masatoshi; Cheng, Ann-Lii; Llovet, Josep M; Finn, Richard S; LeBerre, Marie-Aude; Baumhauer, Annette; Meinhardt, Gerold; Han, Guohong;Resorce Investigators.

  Reference: LANCET 2017; 389(10064):56-66.

• Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution

  Authors: Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J.

  Reference: JOURNAL OF HEPATOLOGY 2016; 65(4):719-726.

• Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection

  Authors: Ferrer-Fabrega, Joana; Forner, Alejandro; Liccioni, Alexandre; Miquel, Rosa; Molina, Victor; Navasa, Miquel; Fondevila, Constantino; Carlos Garcia-Valdecasas, Juan; Bruix, Jordi; Fuster, Josep.

  Reference: HEPATOLOGY 2016; 63(3):839-849.

• Restoring miR122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through Smad-independent TGF-beta pathway

  Authors: Boix, Loreto; Manuel Lopez-Oliva, Juan; Carolina Rhodes, Ana; Bruix, Jordi.

  Reference: Oncotarget 2016; 7(44):71309-71329.